Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin protein of Influenza A Newcastle/1/2021 Strain (HA)
- Target
- HA
- Molecular classification
- Glycoprotein, Viral protein, Surface antigen
01
Overview
The hemagglutinin (HA) protein from the Newcastle/1/2021 strain of Influenza A (H3N2) is a surface glycoprotein essential for viral entry into host cells. It mediates viral attachment to sialic acid receptors and subsequent membrane fusion. As a major antigenic determinant, HA is a primary target for neutralizing antibodies and a key component of influenza vaccines. The Newcastle/1/2021 strain's HA sequence has been used in mRNA vaccine development to elicit protective immune responses against circulating H3N2 variants.
- Other names
- Influenza A H3N2 HemagglutininNewcastle/1/2021 HA protein
02
Mechanism of action
Antibody neutralization of viral binding and entry.
03
Biological functions
Viral attachmentMembrane fusionReceptor bindingAntigen presentationImmune response elicitation
04
Disease associations
InfectionInfluenzaRespiratory disease
05
Safety considerations
Antigenic drift leading to vaccine mismatchPotential for antibody-dependent enhancement (ADE) in certain contexts.
Beyond the preview
Go deeper on Hemagglutinin protein of Influenza A Newcastle/1/2021 Strain (HA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemagglutinin protein of Influenza A Newcastle/1/2021 Strain (HA).